Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic


Follow this company

Companies Mentioned

OTC:BB:CTIX / OTC:BB:ACTC / OTC:BB:PVCT
04/28/2014 [ACCESSWIRE] Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.

The solid showing comes less than two weeks after the Beverly, Mass.-based pharmaceutical company reported favorable results in a recently completed preclinical study evaluating its new antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae.

The research, which is government funded through existing grants to research institutions, is being conducted at a major university in Texas.

In a thigh burden study of a multi-drug resistant strain of Klebsiella pneumoniae in a mouse model, Cellceutix's defensin mimetic compound CTIX1278, was efficacious as compared to a carbapenem antibiotic that is widely used as a last line of defense against drug-resistant, Gram-negative bacteria, including Klebsiella pneumoniae.

 A second study is now being conducted at multiple dosing levels with various infusion parameters with the goal of increasing efficacy and further defining a treatment protocol for the compound.

"This is highly encouraging early data of CTIX1278 as it is the first example of efficacy in vivo with one of our defensin mimetic compounds versus Klebsiella pneumoniae,"  said Dr. Krishna Menon, chief scientific officer at Cellceutix.

On Apr. 25, CTIX’s share price on closed at $1.68, up 9 cents from previous day’s share price of $1.59.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

Advanced Cell Technology’s Dr. Lanza Make Time’s Most Influential People List

In other news, Advanced Cell Technology Inc. (OTCQB: ACTC), a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology,  stock volume was robust Apr. 25, with 8,312,383 changing hands.

On Apr. 24, announced that the Marlborough, Mass.-based company's Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 TIME 100 annual list of the hundred most influential people in the world. The TIME 100 issue, containing the full list hits newsstands on Friday, Apr. 25.

A gala honoring this years' TIME 100 will be held on Tuesday, Apr. 29, 2014 at Jazz at Lincoln Center in New York City. The event brings together the world's leading figures in politics, technology, science, philanthropy, media, business and entertainment and attracts worldwide media coverage.

This honor comes on the heels of the company’s announcement that it has discovered a new method to generate a potent and replenishable population of mesenchymal stem cells (MSCs) from pluripotent stem cells.

Advance Cell’s research appears online ahead of print in Stem Cell and Development, one of the top stem cells journals, published by Mary Ann Liebert Inc. This new and proprietary population of pluripotent stem cell-derived MSCs displays potent immunomodulatory and therapeutic properties and has a greater than 30,000 fold proliferative capacity, relative to ordinary bone marrow-derived MSCs, the most commonly used source for MSCs in clinical trials.

On Apr. 25, ACTC’s share price closed at 6 cents, unchanged from the previous day’s close.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

 

Provectus Pharmaceuticals’ Phase I Breast Cancer Drug Study Is Completed

Meanwhile, Provectus Pharmaceuticals Inc.’s (OTC: PVCT) share price on Apr. 25 closed at $2.27, down 8 cents from the share price of $2.19 cents the previous day.

The development-stage pharmaceutical company is developing medicines for oncology and dermatology applications. Provectus product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis.

In addition it is conducting PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris.

Moreover, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

 

ABOUT US:

Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.

Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.pennypickalerts.com

Disclosure

Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

COMMENTS

Leave a comment...
 * 

Your Name
 *